Subscribe
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma
Issues
2011
August 2011, Vol 2, No 5
August 2011, Vol 2, No 5
Personalized Approach to Mammography Most Cost-Effective, but at What Risk to Women?
Value Propositions
,
Value Peer-spectives
August 2011, Vol 2, No 5
The most recent mammography screening recommendations call on women to begin annual screening for breast cancer at age 40 years, regardless of their risk for the disease.
Read Article
FDA Grants Priority Review for Ruxolitinib for the Treatment of Myelofibrosis
Value Propositions
,
Value Peer-spectives
August 2011, Vol 2, No 5
The US Food and Drug Administration (FDA) has granted priority review for the investigational drug ruxolitinib as a potential treatment for patients with myelofibrosis, a blood cancer with few treatment options.
Read Article
Value of Screening High-Risk Individuals for Lung Cancer Confirmed, but Who Will Pay for It?
Value Propositions
,
Value Peer-spectives
August 2011, Vol 2, No 5
New results from the National Lung Cancer Screening Trial have shown that in individuals at high risk for lung cancer, screening with lowdose computed tomography (CT) significantly reduces mortality in this subpopulation (N Engl J Med. 2011;365:395-409).
Read Article
NICE Backs Value of Thalidomide, Bortezomib for Multiple Myeloma
Value Propositions
,
Value Peer-spectives
August 2011, Vol 2, No 5
In July, the United Kingdom’s National Institute for Health and Clinical Excellence (NICE) approved the use of thalidomide (Thalomid) for the first-line treatment of multiple myeloma in patients in whom high-dose chemotherapy with stem-cell transplantation is deemed inappropriate.
Read Article
Inexpensive Immunochemical Stool Test Effective Option for Colon Cancer Screening
Value Propositions
,
Value Peer-spectives
August 2011, Vol 2, No 5
The immunochemical fecal occult blood test (iFOBT), a new version of the traditional FOBT, has demonstrated 90% specificity in detecting colon growths.
Read Article
77,000 Early Adopters to CMS’s EHR Incentive Program Exceed Requirements, Reflecting Value to Patients and Providers
Value Propositions
,
Value Peer-spectives
August 2011, Vol 2, No 5
Approximately 77,000 healthcare providers have already registered by July of this year with the Centers for Medicare & Medicaid Services (CMS) for the electronic health records (EHRs) program.
Read Article
Addressing Cost and Quality Issues in Novel Treatment Strategies for Non–Small-Cell Lung Cancer: Where Is Our Focused Factory?
By
Ira Klein, MD, MBA, FACP
Commentary
,
Value Peer-spectives
August 2011, Vol 2, No 5
Evidence-based medicine and a focused clinical orientation are key elements to delivering the right care at the right time to the right person. The recent findings reported at the 2011 American Society of Clinical Oncology annual meeting regarding the use of novel therapies and strategies in the treatment of non–small-cell lung cancer make achieving these goals harder than ever.
Read Article
Ipilimumab: A New Era in Metastatic Melanoma Management
By
Timothy G. Tyler, PharmD, FCSHP
Melanoma
,
Personalized Medicine
August 2011, Vol 2, No 5
The development of ipilimumab (Yervoy) and its approval by the US Food and Drug Administration (FDA) in March 2011 have opened a new era in the treatment and management of patients with metastatic melanoma.
Read Article
Colonoscopy Overused in Medicare Recipients, Adding Unnecessary Expenditures
By
Caroline Helwick
Cancer Care
,
Personalized Medicine
August 2011, Vol 2, No 5
Medicare may be paying for more screening colonos - copies than are warranted for the prevention of colorectal cancer (CRC), according to a new study (Goodwin JS, et al. Arch Intern Med. 2011 May 9 [Epub ahead of print]).
Read Article
HBV Screening Recommended with Chemotherapy, but Not Cost-Effective in Solid Tumors
Cancer Care
,
Personalized Medicine
August 2011, Vol 2, No 5
Most professional guidelines now recommend screening for hepatitis B virus (HBV) infection in essentially all patients receiving chemotherapy, but it is seldom performed and is not cost-effective in patients with solid (nonhematologic) tumors, according to studies presented at ASCO 2011.
Read Article
Page 1 of 4
1
2
3
4
View the Latest Issue of VBCC
Read Issue
Top Trending Articles
1.
Navigating the Complex Landscape of Oral Cancer Medication
2.
Luspatercept Yields Improved Transfusion Independence Compared With Epoetin Alfa in Patients With Lower-Risk MDS
Phoebe Starr
3.
Talvey Receives Accelerated Approval for Relapsed or Refractory Multiple Myeloma
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma